Serum Prolactin Levels and Mortality in Adults Without Prolactinoma: A Meta-Analysis
Authors' conclusion
PRL levels seem to be an independent predictor for mortality. Further validation is warranted before its role as a risk-stratification tool can be delineated in clinical practice.
Study context
- Population
- Adults without prolactinoma with serum prolactin (PRL) measured for risk-stratification; literature search up to June 10, 2023
- Participants
- 23,596 adults14 studies
- Comparison
- Higher vs lower serum PRL levels
- Outcome
- All-cause and CV mortality (aHRs)
- Follow-up
- During
Methodological detailsrandom-effects meta-analysis, 28 studies eligible; 14 with appropriate data for meta-analysis
- Random-effects meta-analysis
- 28 studies eligible; 14 with appropriate data for meta-analysis
Pooled result
As reported in the abstract
Highest PRL category vs Lowest PRL categoryEstimate (CI)
I2 = 65%
pooled aHR, all-cause mortality 1.81(1.43–2.30)
I2 = 82%
pooled aHR, CV mortality 1.59(1.04–2.42)
- Per unit PRL increase, all-cause mortality: pooled aHR (I2 = 48%)
- 1.17 [1.08-1.27]
- Per unit PRL increase, CV mortality: pooled aHR (I2 = 89%)
- 1.54 [1.14-2.09]
Further pooled results
- Association between PRL levels and in-hospital death did not reach statistical significance
Original publication
Serum Prolactin Levels and Mortality in Adults Without Prolactinoma: A Meta-Analysis. J Clin Endocrinol Metab. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →